Recent insider share sale and lack of insider buying in the past year may concern investors. Despite some alignment between management and smaller shareholders, caution is advised due to recent insider selling activity.
Pacira BioSciences' moderate net income growth is seen as a positive despite a low ROE. The growth could be due to good management decisions or a low payout ratio, as it doesn't pay dividends. Analysts predict future earnings momentum.
Multiple insiders selling shares over the past year could be a red flag. However, insider ownership level shows alignment between management and smaller shareholders. Lack of insider purchases in the past year calls for caution.
$Pacira BioSciences(PCRX.US)$$Flexion Therapeutics Inc(FLXN.US)$On October 12, Pacira BioSciences announced that it has entered into a definitive agreement to acquire Flexion Therapeutics For $8.50 per share, or approximately $430 million, in cash to enhance its non-opioid pain portfolio. The deal also includes contingent valuable rights worth up to $8.00 per share, which are tied to Zilretta sales targets and FDA approvals for FX201 and FX301.
Pacira BioSciences股票討論區
2023Q1營收增長1.5%,營業利潤大幅下滑58.5%,淨利潤進入虧損區間。
目前市盈率117,即使以2021年0.42億淨利高點計算,市盈率也達到了43,缺乏吸引力。
暫無評論